©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 14, 2012; 18(42): 6060-6069
Published online Nov 14, 2012. doi: 10.3748/wjg.v18.i42.6060
Published online Nov 14, 2012. doi: 10.3748/wjg.v18.i42.6060
Table 1 New agents against hepatitis C virus currently evaluated in phase II or III trials
| Drug | Company |
| NS3/4A protease inhibitors | |
| First generation, linear | |
| Boceprevir (Approved) | MERCK |
| Telaprevir (Approved) | JANSSEN |
| Narlaprevir | MERCK |
| First generation, macrocyclic | |
| BI201335 | BOEHRINGER Ingelheim |
| TMC435 | TIBOTEC/JANSSEN |
| Danoprevir | ROCHE |
| Vaniprevir | MERCK |
| Asunaprevir | BRISTOL-MYERS SQUIBB |
| ABT-450 | ABBOTT |
| GS-9451 | GILEAD |
| GS-9256 | GILEAD |
| ACH-1625 | ACHILLION |
| Second generation, macrocyclic | |
| MK-5172 | MERCK |
| Nucleos(t)ide analogue inhibitors of HCV polymerase | |
| PSI/GS-7977 | PHARMASSET/GILEAD |
| Mericitabine | ROCHE |
| IDX-184 | IDENIX |
| Non-nucleoside analogue inhibitors of HCV polymerase | |
| Tegobuvir | GILEAD |
| Filibuvir | PFIZER |
| ANA-598/Setrobuvir | ANADYS/ROCHE |
| BI207127 | BOEHRINGER Ingelheim |
| ABT-333 | ABBOTT |
| ABT-072 | ABBOTT |
| VX-222 | VERTEX |
| NS5A inhibitors | |
| Daclatasvir | BRISTOL-MYERS SQUIBB |
| GS-5885 | GILEAD |
| GSK2336805 | GSK |
| Cyclophilin inhibitors | |
| Alisporivir1 | NOVARTIS |
| SCY-635 | Scynexis |
- Citation: Alexopoulou A, Papatheodoridis GV. Current progress in the treatment of chronic hepatitis C. World J Gastroenterol 2012; 18(42): 6060-6069
- URL: https://www.wjgnet.com/1007-9327/full/v18/i42/6060.htm
- DOI: https://dx.doi.org/10.3748/wjg.v18.i42.6060